[1] Zhang JB, Chen J, Zhou J, et al. Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis. World J Clin Cases, 2021, 9(19):5179-5190. [2] Malakar S, Mathur A, Agarwal A, et al. Budd-Chiari syndrome with portal vein thrombosis managed successfully with direct intrahepatic portosystemic shunt: a case report and review of the literature. J Clin Exp Hepatol, 2023, 13(5):917-920. [3] Tejedor-Tejada J, Fuentes-Valenzuela E, García-Pajares F, et al. Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt. Gastroenterol Hepatol, 2021, 44(9):620-627. [4] 赵晨,张庆桥,徐浩,等.采用Viabahn支架行经颈静脉肝内门体分流术治疗肝静脉广泛闭塞布加综合征的疗效分析.中华肝脏病杂志,2021,29(10):972-976. [5] Dong H, Zhang C, Li Z, et al. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: a preliminary study. J Cancer Res Ther, 2021, 17(3):784-789. [6] 邵玉,田思雨,孙志霞,等.常规超声联合CEUS在经颈静脉肝内门体分流术术后随访中的临床应用.中华老年多器官疾病杂志,2020,19(8):617-618. [7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39. [8] European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol, 2016, 64(1):179-202. [9] Gao L, Li MB, Li JY, et al. Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria. World J Gastroenterol, 2023, 29(38):5383-5394. [10] Gunarathne LS, Rajapaksha IG, Casey S, et al. Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic rats. Hepatol Commun, 2022, 6(9):2523-2537. [11] Vukotic R, Di Donato R, Roncarati G, et al. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial. J Hepatol, 2023, 79(4):977-988. [12] 周昊,姚欣,汤善宏,等.43例采用Viatorr支架行经颈静脉肝内门体分流术的临床研究.中华肝脏病杂志,2021,29(1):54-59. [13] Matthaiou N, Galanakis N, Kehagias E, et al. Endovasculartreatment of malignant superior vena cava syndrome through upper-limb access: A comparison between venous-dedicated and conventional stents. J Vasc Interv Radiol, 2020, 31(12):2066-2072. [14] Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol, 2021, 74(5):1188-1199. [15] Habibollahi P, Shamchi SP, D'souza J, et al. Predictive value of abnormal findings on covered transjugular intrahepatic portosystemic shunt baseline doppler sonography. Ultrasound Q, 2020, 36(1):74-78. [16] 韩浩,杨建,龚黎,等.常规超声检查联合剪切波弹性成像技术在经颈静脉肝内门体静脉分流术中的应用价值.中华医学超声杂志(电子版),2016,13(12):904-906. [17] Han H, Yang J, Jin WK, et al. Diagnostic value of conventional ultrasound and shear wave elastography in detecting transjugular intrahepatic portosystemic shunt dysfunction. Acta Radiol, 2021, 62(12):1575-1582. [18] 王艳华,王涌臻.彩色多普勒超声在经颈静脉肝内门体分流术联合食管胃底曲张静脉栓塞术后随访中的应用.中国临床研究,2017,30(9):1225-1227. [19] Li T, Mao Y, Zhao B, et al. Value of contrast-enhanced ultrasound for diagnosis and follow-up of renal artery stenosis in patients with chronic kidney disease. Abdom Radiol (NY), 2022, 47(5):1853-1861. [20] Zhan PC, Li Z, Li X, et al. A nomogram to predict the risk of stent dysfunction after TIPS in patients with hepatitis B cirrhosis. Acad Radiol, 2022, 29(10):1532-1540. [21] Morosetti D, Lenci I, Argirò R, et al. Use of intravascular ultrasound to improve diagnosis and treatment of transjugular intrahepatic portosystemic shunt dysfunction in patients in the long-term follow-up. Euroasian J Hepatogastroenterol, 2022, 12(1):50-56. |